Montefiori, L., lacobucci, I., Budhraja, A., Moore, J., Baskin, R., DeVries, R., . . . Mullighan, C. (2022). ALL-090 Highly Effective Combination of FLT3 and BCL2 Inhibitors in a Preclinical Model of Lineage Ambiguous Leukemia. Clinical lymphoma, myeloma and leukemia, 22, S193-S194. https://doi.org/10.1016/S2152-2650(22)01182-X
Citace podle Chicago (17th ed.)Montefiori, Lindsey, et al. "ALL-090 Highly Effective Combination of FLT3 and BCL2 Inhibitors in a Preclinical Model of Lineage Ambiguous Leukemia." Clinical Lymphoma, Myeloma and Leukemia 22 (2022): S193-S194. https://doi.org/10.1016/S2152-2650(22)01182-X.
Citace podle MLA (9th ed.)Montefiori, Lindsey, et al. "ALL-090 Highly Effective Combination of FLT3 and BCL2 Inhibitors in a Preclinical Model of Lineage Ambiguous Leukemia." Clinical Lymphoma, Myeloma and Leukemia, vol. 22, 2022, pp. S193-S194, https://doi.org/10.1016/S2152-2650(22)01182-X.